Celcuity
-
Celcuity Stock Skyrockets Following Breakthrough Breast Cancer Drug Trial Results
Celcuity Inc. (NASDAQ: CELC) shares surged over 100% after the company announced breakthrough Phase 3 trial results for its breast cancer drug, gedatolisib. The trial demonstrated unprecedented efficacy in slowing disease progression in advanced breast cancer patients.